title: Deferred treatment for prostate cancer.
abstract: The clinical outcome of 278 prostate cancer patients managed by a deferred treatment policy was analysed retrospectively. Following TURP or biopsy, all patients were asymptomatic and deemed suitable for management by a deferred treatment policy, i.e. hormone therapy or other forms of treatment were only initiated if and when symptomatic progression occurred. The overall 5-year survival rate was 30%; 18% of patients died from other causes without needing treatment for their prostate cancer; 11% were alive and untreated after 5 years' follow-up; 17% died from prostate cancer without further treatment. Poor tumour grade, anaemia, metastatic disease, a short history, presentation with retention, and a raised serum creatinine at presentation were associated with a poor prognosis.
authors.affiliation: Department of Urology, Freeman Hospital, Newcastle upon Tyne.
authors.forename: R
authors.initials: R
authors.lastname: Handley
authors.forename: T W
authors.initials: TW
authors.lastname: Carr
authors.forename: D
authors.initials: D
authors.lastname: Travis
authors.forename: P H
authors.initials: PH
authors.lastname: Powell
authors.forename: R R
authors.initials: RR
authors.lastname: Hall
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000401:mortality / Q000628:therapy*; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors